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Several studies show that dihydroergotamine (DHE) pro-
duces sustained migraine pain relief, measured up to 48
hours, although its serum half-life is only 10-13 hours.
The extended duration of action has been attributed to
an active metabolite (8’-OH-DHE) with a much longer
half-life than the parent compound. However, recent
pharmacokinetic studies demonstrate that DHE metabo-
lites measured in humans are too low to have substan-
tial clinical effect and probably do not contribute to
sustained efficacy. We hypothesized that the long-lasting
effect of DHE is most likely due to prolonged binding to
receptors, rather than serum half-life. Therefore, to
investigate the mechanism of sustained migraine pain
relief observed with DHE, we compared its duration of
binding to serotonin receptors vs. sumatriptan.
Duration of receptor binding is expressed as the disso-
ciation constant (koff) of the receptor-ligand complex,
measured using a competitive radioligand assay. DHE
and sumatriptan were tested with human 5-HT1B and
5-HT1D receptors in this study. The dissociation half-
life of DHE on 5-HT1B and 5-HT1D receptors is
approximately 10 times longer than that of sumatriptan
(5-HT1B: 1.38 h for DHE vs. 0.17 h for sumatriptan; 5-
HT1D: 1.28 h for DHE vs. 0.09 h for sumatriptan). DHE
binds to 5-HT1B and 5-HT1D receptors up to 8-14
times longer than does sumatriptan. These receptors
play a key role in the acute treatment of migraine and,
therefore, prolonged binding to these receptors may be
a mechanism for the sustained pain relief seen with
DHE during the acute treatment of migraine.
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